AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?
Key PointsDividend payments offer you security in difficult markets -- and extra growth in better times.
Dividend stocks are a valuable addition to any investment portfolio, providing investors with a steady stream of passive income regardless of market conditions. This consistent income can help offset losses in a portfolio during challenging market periods and enhance returns during more favorable market conditions, making such stocks a reliable and attractive investment.
Dividend stocks can be found across various industries, but they are particularly prevalent in the healthcare sector. This is largely due to the fact that healthcare companies, often top pharmaceutical firms, are typically well-established, stable businesses that prioritize shareholder returns over aggressive growth. Two prominent examples of such dividend-paying companies are AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE).
Both have a strong commitment to returning profits to shareholders, but determining which of these two pharmaceutical giants constitutes the better investment opportunity in September requires a closer examination. To make an informed decision, it is crucial to analyze the financial health, dividend yields, growth prospects, and other relevant factors of each company.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
